Marker Therapeutics Receivables

Marker Therapeutics (MRKR) currently reports a receivables of $1.4M as of March 2026. That compares with $2.5M in the prior-year period — down 44.0% year over year. Use the charts on this page to explore Marker Therapeutics's receivables history and peer comparisons.

Marker Therapeutics's receivables decreased from $2.5M to $1.4M — a 44.0% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Marker Therapeutics reported $1.4M in receivables as of March 2026. That compares with $2.5M in the prior-year period — down 44.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $1.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Marker Therapeutics, and consider following MRKR for alerts when major investors trade the stock.

Marker Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $1.4M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MRKR with unrelated industries.